Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5954-5964

  Kuo, Yung Chih ^a   Wang, Cheng Ting ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Blood brain barrier; Lactoferrin; Liposome; Neuron growth factor; SK N MC cell

Indexed keywords

BLOOD; ENDOTHELIAL CELLS; GLYCOPROTEINS; LIPOSOMES; NEURODEGENERATIVE DISEASES; NEURONS; PARTICLE SIZE; PEPTIDES; ZETA POTENTIAL;

ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; ENTRAPMENT EFFICIENCY; HUMAN BRAIN-MICROVASCULAR ENDOTHELIAL CELLS; LACTOFERRIN; LOADING EFFICIENCY; NEURON GROWTH FACTORS; PHYSICAL STABILITY;

CYTOLOGY;

AMYLOID BETA PROTEIN; CHOLESTEROL; LACTOFERRIN; LIPOSOME; NERVE GROWTH FACTOR; NITROGEN; PHOSPHORUS;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MICROVASCULAR ENDOTHELIAL CELL; NERVE CELL DEGENERATION; NEUROTOXICITY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BLOOD-BRAIN BARRIER; CELL LINE; CELL SURVIVAL; HUMANS; LACTOFERRIN; LIPOSOMES; NERVE GROWTH FACTORS;

EID: 84899986367     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.082     Document Type: Article

References (49)

1. Thies W., Bleiler L., Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9:208-245.
2. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007, 8:663-672.
3. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009, 10:333-344.
4. Deane R., Sagare A., Zlokovic B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer's disease. Curr Pharm Des 2008, 14:1601-1605.
5. Bottger D., Ullrich C., Humpel C. Monocytes deliver bioactive nerve growth factor through a brain capillary endothelial cell-monolayer invitro and counteract degeneration of cholinergic neurons. Brain Res 2010, 1312:108-119.
6. Koliatsos V.E., Nauta H.J., Clatterbuck R.E., Holtzman D.M., Mobley W.C., Price D.L. Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. JNeurosci 1990, 10:3801-3813.
7. Charles V., Mufson E.J., Friden P.M., Bartus R.T., Kordower J.H. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res 1996, 728:193-203.
8. Jonhagen M.E., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998, 9:246-257.
9. Granholm A.C., Albeck D., Backman C., Curtis M., Ebendal T., Friden P., et al. Anon-invasive system for delivering neural growth factors across the blood-brain barrier: a review. Rev Neurosci 1998, 9:31-55.
10. Schnyder A., Huwyler J. Drug transport to brain with targeted liposomes. Neurotherapeutics 2005, 2:99-107.
11. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
12. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
13. Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R., et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomed-Nanotechnol Biol Med 2011, 7:551-559.
14. Ward P.P., Paz E., Conneely O.M. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005, 62:2540-2548.
15. Fillebeen C., Descamps L., Dehouck M.P., Fenart L., Benaissa M., Spik G., et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. JBiol Chem 1999, 274:7011-7017.
16. Kawamata T., Tooyama I., Yamada T., Walker D.G., McGeer P.L. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol 1993, 142:1574-1585.
17. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995, 92:9603-9607.
18. Ji B., Maeda A., Higuchi M., Inoue K., Akita H., Harashima H., et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life Sci 2006, 78:851-855.
19. Kuo Y.C., Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 2007, 340:143-152.
20. Kuo Y.C., Lu C.H. Effect of human astrocytes on the characteristics of human brain-microvascular endothelial cells in the blood-brain barrier. Colloids Surf B 2011, 86:225-231.
21. Lopez-Pinto J.M., Gonzalez-Rodriguez M.L., Rabasco A.M. Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm 2005, 298:1-12.
22. Wei M., Xu Y., Zou Q., Tu L., Tang C., Xu T., et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Biopharm 2012, 46:131-141.
23. Chen H.L., Tang L., Qin Y., Yin Y.J., Tang J., Tang W.W., et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci 2010, 40:94-102.
24. Anabousi S., Laue M., Lehr C.M., Bakowsky U., Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm 2005, 60:295-303.
25. Yousefi A., Esmaeili F., Rahimian S., Atyabi F., Dinarvand R. Preparation and invitro evaluation of a pegylated nano-liposomal formulation containing docetaxel. Sci Pharm 2009, 77:453-464.
26. Meenach S.A., Vogt F.G., Anderson K.W., Hilt J.Z., McGarry R.C., Mansour H.M. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable DPPC and DPPC: DPPE-PEG microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomed 2013, 8:275-293.
27. Liu Z., Jiang M., Kang T., Miao D., Gu G., Song Q., et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013, 34:3870-3881.
28. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: invitro and invivo evaluations. JControl Release 2009, 134:55-61.
29. Messina G.M.L., Satriano C., Marletta G. Amultitechnique study of preferential protein adsorption on hydrophobic and hydrophilic plasma-modified polymer surfaces. Colloids Surf B 2009, 70:76-83.
30. Moribe K., Maruyama K., Iwatsuru M. Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives. Int J Pharm 1999, 188:193-202.
31. Agarwal R., Katare O.P., Vyas S.P. Preparation and invitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001, 228:43-52.
32. Ramana L.N., Sethuraman S., Ranga U., Krishnan U.M. Development of a liposomal nanodelivery system for nevirapine. JBiomed Sci 2010, 17:1-9.
33. Mourtas S., Fotopoulou S., Duraj S., Sfika V., Tsakiroglou C., Antimisiaris S.G. Liposomal drugs dispersed in hydrogels: effect of liposome, drug and gel properties on drug release kinetics. Colloids Surf B 2007, 55:212-221.
34. Jain S.K., Jain R.K., Chourasia M.K., Jain A.K., Chalasani K.B., Soni V., et al. Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS PharmSciTech 2005, 6:E35-E41.
35. Zhao L., Feng S.S. Effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within the lipid monolayer at the air-water interface. JColloid Interface Sci 2006, 300:314-326.
36. Kim C.W., Son K.N., Choi S.Y., Kim J. Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-A-mediated endothelial cell proliferation and migration. FEBS Lett 2006, 580:4332-4336.
37. Tang L., Cui T.J., Wu J.J., Liu-Mares W., Huang N., Li J. Arice-derived recombinant human lactoferrin stimulates fibroblast proliferation, migration, and sustains cell survival. Wound Repair Regen 2010, 18:123-131.
38. Huang R.Q., Han L., Li J.H., Ren F.L., Ke W.L., Jiang C., et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. JGene Med 2009, 11:754-763.
39. Kuo Y.C., Ko H.F. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials 2013, 34:4818-4830.
40. Kuner P., Hertel C. NGF induces apoptosis in a human neuroblastoma cell line expressing the neurotrophin receptor p75NTR. JNeurosci Res 1998, 54:465-474.
41. Kim D.H., Richardson-Burns S.M., Hendricks J.L., Sequera C., Martin D.C. Effect of immobilized nerve growth factor on conductive polymers: electrical properties and cellular response. Adv Funct Mater 2007, 17:79-86.
42. Shaykhalishahi H., Taghizadeh M., Yazdanparast R., Chang Y.T. Anti-amyloidogenic effect of AA3E2 attenuates β-amyloid induced toxicity in SK-N-MC cells. Chem-Biol Interact 2010, 186:16-23.
43. Moongkarndi P., Srisawat C., Saetun P., Jantaravinid J., Peerapittayamongkol C., Soi-ampornkul R., et al. Protective effect of mangosteen extract against β-amyloid-induced cytotoxicity, oxidative stress and altered proteome in SK-N-SH cells. JProteome Res 2010, 9:2076-2086.
44. Arancibia S., Silhol M., Mouliere F., Meffre J., Hollinger I., Maurice T., et al. Protective effect of BDNF against beta-amyloid induced neurotoxicity invitro and invivo in rats. Neurobiol Dis 2008, 31:316-326.
45. Wakabayashi M., Matsuzaki K. Formation of amyloids by Aβ-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. JMol Biol 2007, 371:924-933.
46. Herz J., Bock H.H. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002, 71:405-434.
47. Deane R., Wu Z., Sagare A., Davis J., Yan S.D., Hamm K., et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 2004, 43:333-344.
48. 1-42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002, 110:199-211.
49. Wang L., Sato H., Zhao S., Tooyama I. Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Neurosci Lett 2010, 481:164-167.